DE69701139D1 - Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität - Google Patents

Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität

Info

Publication number
DE69701139D1
DE69701139D1 DE69701139T DE69701139T DE69701139D1 DE 69701139 D1 DE69701139 D1 DE 69701139D1 DE 69701139 T DE69701139 T DE 69701139T DE 69701139 T DE69701139 T DE 69701139T DE 69701139 D1 DE69701139 D1 DE 69701139D1
Authority
DE
Germany
Prior art keywords
lofexidin
hyperactivity
concentrated
treating
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69701139T
Other languages
English (en)
Other versions
DE69701139T2 (de
Inventor
Amy Arnsten
Keith Davies
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Britannia Pharmaceuticals Ltd
Original Assignee
Britannia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Britannia Pharmaceuticals Ltd filed Critical Britannia Pharmaceuticals Ltd
Publication of DE69701139D1 publication Critical patent/DE69701139D1/de
Application granted granted Critical
Publication of DE69701139T2 publication Critical patent/DE69701139T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
DE69701139T 1996-06-25 1997-06-24 Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität Expired - Lifetime DE69701139T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613243.6A GB9613243D0 (en) 1996-06-25 1996-06-25 Attention deficit hyperactive disorder
PCT/GB1997/001713 WO1997049396A1 (en) 1996-06-25 1997-06-24 Use of lofexidine in the manufacture of a medicament for treating attention deficit hyperactive disorder

Publications (2)

Publication Number Publication Date
DE69701139D1 true DE69701139D1 (de) 2000-02-17
DE69701139T2 DE69701139T2 (de) 2000-09-28

Family

ID=10795815

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69701139T Expired - Lifetime DE69701139T2 (de) 1996-06-25 1997-06-24 Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität

Country Status (7)

Country Link
EP (1) EP0896536B1 (de)
AT (1) ATE188608T1 (de)
AU (1) AU715790B2 (de)
DE (1) DE69701139T2 (de)
ES (1) ES2142169T3 (de)
GB (2) GB9613243D0 (de)
WO (1) WO1997049396A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090246256A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
EP2363116A1 (de) * 2008-06-25 2011-09-07 US Worldmeds LLC Lofexidin enthaltende Formulierungen mit verzögerter Freisetzung zur oralen Verabreichung
WO2010016844A1 (en) * 2008-08-08 2010-02-11 Agean Llc Lofexidine enantiomers for use as a treatment for cns disease and pathologies and its chiral synthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4382946A (en) * 1981-12-14 1983-05-10 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US4800209A (en) * 1981-12-14 1989-01-24 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder

Also Published As

Publication number Publication date
GB2318976A (en) 1998-05-13
EP0896536B1 (de) 2000-01-12
AU3268497A (en) 1998-01-14
WO1997049396A1 (en) 1997-12-31
GB2318976B (en) 1999-10-13
GB9713344D0 (en) 1997-08-27
ATE188608T1 (de) 2000-01-15
EP0896536A1 (de) 1999-02-17
GB9613243D0 (en) 1996-08-28
AU715790B2 (en) 2000-02-10
DE69701139T2 (de) 2000-09-28
ES2142169T3 (es) 2000-04-01

Similar Documents

Publication Publication Date Title
ATE275948T1 (de) Verwendung von adamantan derivaten zur herstellung eines medikaments zur glaukombehandlung
DE122005000011I1 (de) Verwendung von Tomoxet in zur Behandlung von Hyperaktivit{t mit Aufmerksamkeitsstörungen.
SE9102979L (sv) Saett att behandla avloppsvatten
DE50310078D1 (de) Verwendung von 2,6-di-tert.-butyl-p-kresol zur erh
IL177286A0 (en) Albumin-purification method comprising a nanofiltration step, solution, and composition for therapeutic use containing same
ATE274916T1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE198588T1 (de) Der gebrauch von dialdehyden und hieraus erhaltene acetaten zur inhibierung der peroxidzersetzung in der herstellung und behandlung von zurückgewonnener faserpulpe und anderer faserpulpe
DE69701139D1 (de) Verwendung von lofexidin zur herstellung eines arzneimittels zur behandkung der mit konzentrationsschwäche einhergehenden hyperaktivität
ATE413416T1 (de) Verfahren zur herstellung von niedermolekularem heparin
BR9000085A (pt) Processo para a producao de peroxido de hidrogenio
ATE465998T1 (de) Verfahren zur herstellung und reinigung von 1,7'- dimethyl-2'-propyl-2,5'-bi-1h-benzimidazol
NO20012854L (no) Fremgangsmåte for avvanning av organiske v¶sker
ATE252392T1 (de) Verwendung des lysozym-dimers zur herrstellung eines arzneimittels zur modulation der naturlichen abwehrvorgänge.
ATE69163T1 (de) Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen.
FR2891140B1 (fr) Procede de traitement des fibres keratiniques par application d'un melange eau liquide/vapeur d'eau
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE59906979D1 (de) Verfahren zurHerstellung eines bioaktiven Verbundprodukt auf der Basis von Zeolithmehl
FI956346A (fi) Menetelmä hienodispergoitujen kiintoaineiden konsentraation vähentämiseksi paperinvalmistuksen prosessiliuoksissa
KR910008138A (ko) 효소법에 의한 l-세린의 제조법
ES430126A1 (es) Un procedimiento para la desinfeccion rapida de un suminis- tro de agua que esta contaminado con microorganismos.
DE69813137D1 (de) Pflanzenextrakt, verfahren zu dessen herstellung und seine verwendungen in der human- und tiermedizin
KR970021040A (ko) 유기성폐기물을 이용한 유기질 비료의 제조방법
SE9903416D0 (sv) A process for the production of chemical pulp
BOEHMKE EXPERIENCE WITH THE DETERMINATION OF THE BIOCHEMICAL OXYGEN DEMAND WITH SPECIAL CONSIDERATION OF THE MODIFIED'VIEHL DILUTION METHOD,(ERFAHRUNGEN MIT DER BESTIMMUNG DES BIOCHEMISCHEN SAUERSTOFFEBEDARFS UNTER BESONDERER BERUECKSIGHTIGUNG DER MODIFIZIERTEN VIEHL'SCHEN VERDUENNUNGSMETHODE)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition